What is the optimal duration of treatment with anti-CGRP mAbs to determine their efficacy for each individual patient?

What is the optimal duration of treatment with anti-CGRP mAbs to determine their efficacy for each individual patient?

Cerebral Torque

The introduction of anti-CGRP monoclonal antibodies (mAbs) has revolutionized migraine preventive treatment, offering hope to many patients who have struggled to find relief. However, one question that often arises is: what is the optimal duration of treatment with anti-CGRP mAbs to determine their efficacy for each individual patient?

A recent multicenter, prospective, observational study published in the Journal of Neurology provides valuable insights into this question. The study included 572 patients with high-frequency episodic migraine (HFEM), defined as 8-14 migraine days per month, or chronic migraine (CM), characterized by 15 or more headache days per month, with at least 8 of those days meeting the criteria for migraine. All participants had a history of multiple prior treatment failures.

The study found that while 60.5% of patients responded to anti-CGRP mAbs within 12 weeks (defined as a ≥50% reduction in monthly migraine or headache days), and an additional 15% responded within 24 weeks, a significant proportion of patients (15.7%) were "ultra-late responders," achieving a response only after 24 weeks of treatment. Only 8.7% of patients did not respond to treatment at any point up to 48 weeks.

These findings challenge the current paradigm of migraine prophylaxis, which typically assesses treatment efficacy after just 2-3 months. The authors suggest that for patients who show some improvement (e.g., a ≥30% reduction in monthly migraine or headache days), but do not achieve a full response within this timeframe, continuing treatment for up to 6 months or longer may be beneficial.

The study also identified several characteristics that were more common among ultra-late responders, such as higher BMI, longer duration of medication overuse/adaptation headache, less severe migraine features, more dopaminergic symptoms (defined as ≥ 1 of the following symptoms during the prodrome, headache phase, or postdrome: yawning, somnolence, nausea, vomiting, mood changes, fatigue or diuresis), and a higher prevalence of psychiatric comorbidities. The authors hypothesize that the delayed response in these patients may be due to reduced trigeminal sensitization and/or increased central CGRP activity, which may require more time to be effectively modulated by anti-CGRP mAbs.

Therefore, for some patients, a longer trial of anti-CGRP mAbs may be warranted before considering alternative therapies. This is particularly relevant given the favorable safety and tolerability profile of these medications, which allows for extended use without significant risks.

Back to blog
  • My 6 Favorite HeadaTerm 2 Features

    My 6 Favorite HeadaTerm 2 Features

    Cerebral Torque

    HeadaTerm 2: FDA-Cleared Migraine Relief for less than $80 Use code: CEREBRALTORQUE for 20% OFF! Get HeadaTerm 2 Now Your browser does not support the video tag. Uses the same eTNS technology...

    My 6 Favorite HeadaTerm 2 Features

    Cerebral Torque

    HeadaTerm 2: FDA-Cleared Migraine Relief for less than $80 Use code: CEREBRALTORQUE for 20% OFF! Get HeadaTerm 2 Now Your browser does not support the video tag. Uses the same eTNS technology...

  • The Two Migraine Pathophysiology Theories

    Cerebral Torque

    Migraine Pathophysiology Theories

    The Two Migraine Pathophysiology Theories

    Cerebral Torque

    Migraine Pathophysiology Theories

  • Cortical Spreading Depression Video Study Guide

    Cortical Spreading Depression Video Study Guide

    Cerebral Torque

    (Scroll down for video) Important Concepts: Definition of Cortical Spreading Depression (CSD): A wave of neuronal and glial depolarization that slowly progresses across the cerebral cortex. Role in Migraine: CSD...

    Cortical Spreading Depression Video Study Guide

    Cerebral Torque

    (Scroll down for video) Important Concepts: Definition of Cortical Spreading Depression (CSD): A wave of neuronal and glial depolarization that slowly progresses across the cerebral cortex. Role in Migraine: CSD...

  • A Breakthrough on the Horizon: PACAP-Targeting Antibodies Offer New Promise for Migraine Prevention

    A Breakthrough on the Horizon: PACAP-Targeting ...

    Cerebral Torque

    Migraine patients may soon have a new treatment option. Recent clinical trials show promising results for Lu AG09222, a monoclonal antibody targeting PACAP, a neuropeptide involved in migraine pathophysiology.

    A Breakthrough on the Horizon: PACAP-Targeting ...

    Cerebral Torque

    Migraine patients may soon have a new treatment option. Recent clinical trials show promising results for Lu AG09222, a monoclonal antibody targeting PACAP, a neuropeptide involved in migraine pathophysiology.

1 of 4